Alpha 2.0
Login Register
» Authors » Joachim Peter Steinbach

Joachim Peter Steinbach

Explore the profile of Joachim Peter Steinbach including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 791
Followers 0
Related Specialties
Oncology
General Medicine
Neurology
Top 10 Co-Authors
Ulrich Herrlinger
Peter Hau
Theophilos Tzaridis
Niklas Schafer
Martin Glas
Roland Goldbrunner
Dietmar Krex
Johannes Weller
Walter Stummer
Norbert Galldiks
Published In
Lancet Oncol
J Neurooncol
Lancet
Neuro Oncol
Neurooncol Pract
Affiliations
Soon will be listed here.
Recent Articles
1.
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide
Zeyen T, Bohm L, Paech D, Schafer N, Tzaridis T, Duffy C, et al.
Neuro Oncol . 2024 Oct; 27(2):557-566. PMID: 39351820
Background: Maximum tumor resection improves overall survival (OS) in patients with glioblastoma. The extent of resection (EOR) is historically dichotomized. The response assessment in neuro-oncology (RANO) resects group recently proposed...
2.
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Zeyen T, Paech D, Weller J, Schafer N, Tzaridis T, Duffy C, et al.
J Neurooncol . 2023 Nov; 165(2):387. PMID: 37921974
No abstract available.
3.
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Zeyen T, Paech D, Weller J, Schafer N, Tzaridis T, Duffy C, et al.
J Neurooncol . 2023 Sep; 164(3):607-616. PMID: 37728779
Purpose: In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and pseudoprogression rates (about 10%) were...
4.
Chemotherapy for adult patients with spinal cord gliomas
Gramatzki D, Felsberg J, Hentschel B, Bahr O, Westphal M, Schackert G, et al.
Neurooncol Pract . 2021 Jul; 8(4):475-484. PMID: 34277025
Background: The incidence of spinal cord gliomas, particularly in adults is low, and the role of chemotherapy has remained unclear. Methods: We performed a multicenter, retrospective study of 21 patients...
5.
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Weller J, Tzaridis T, Mack F, Steinbach J, Schlegel U, Hau P, et al.
Lancet Oncol . 2019 Sep; 20(10):1444-1453. PMID: 31488360
Background: The CeTeG/NOA-09 trial showed significantly longer overall survival with combined lomustine-temozolomide therapy compared with standard temozolomide for patients with glioblastoma with methylated MGMT promoter. The trial also aimed to...
6.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Herrlinger U, Tzaridis T, Mack F, Steinbach J, Schlegel U, Sabel M, et al.
Lancet . 2019 Feb; 393(10172):678-688. PMID: 30782343
Background: There is an urgent need for more effective therapies for glioblastoma. Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus radiotherapy might be superior to temozolomide...
7.
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Stupp R, Hegi M, Gorlia T, Erridge S, Perry J, Hong Y, et al.
Lancet Oncol . 2014 Aug; 15(10):1100-8. PMID: 25163906
Background: Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in...